Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists

Nagler, M; Angelillo-Scherrer, A; Méan, M; Limacher, Andreas; Abbal, C; Righini, Marc Philip; Beer, J H; Osterwalder, J; Frauchiger, B; Aschwanden, M; Matter, C M; Kucher, N; Cornuz, Jacques; Banyai, M; Husmann, M; Staub, D; Mazzolai, L; Hugli, O; Rodondi, N; Aujesky, D

doi:10.1111/jth.13810

Scientific article

English

Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists

Published inJournal of Thrombosis and Haemostasis, vol. 15, p. 2165-2175

Publication date2017

Abstract

The long-term effect of polymorphisms of the vitamin K-epoxide reductase (VKORC1) and the cytochrome P450 enzyme gene (CYP2C9) on clinical outcomes remains unclear.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

La maladie thromboembolique veineuse (808)

Citation (ISO format)

NAGLER, M et al. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. In: Journal of Thrombosis and Haemostasis, 2017, vol. 15, p. 2165–2175. doi: 10.1111/jth.13810

Article (Published version)

Identifiers

PID : unige:99342
DOI : 10.1111/jth.13810
PMID : 28834238

Journal ISSN1538-7836

476views

0downloads

Creation30/08/2017 12:27:00

First validation30/08/2017 12:27:00

Update time27/01/2025 15:24:53

Status update27/01/2025 15:24:53

Last indexation27/01/2025 15:35:43

Archive ouverte UNIGE

Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists

The long-term effect of polymorphisms of the vitamin K-epoxide reductase (VKORC1) and the cytochrome P450 enzyme gene (CYP2C9) on clinical outcomes remains unclear.

Technical informations